偶然发现放射治疗后乳房中的 [99mTc]Tc-MIBI 摄取，且没有癌症复发。
Incidental finding of [99mTc]Tc-MIBI uptake in a post-radiotherapy breast without recurrence of cancer.
发表日期：2023
作者：
Marek Cacko, Katarzyna Jóźwik-Plebanek, Jacek Wnuk, Anna Teresinska
来源：
Cellular & Molecular Immunology
摘要：
[99mTc]Tc-MIBI 的嗜瘤性质使得这种放射性药物可用于癌症诊断，特别是乳腺癌。在针对非肿瘤适应症进行的测试中，[99mTc]Tc-MIBI 的摄取增加总是会引起对其肿瘤特征的怀疑，并需要进一步的临床诊断，这对于既往有癌症病史的患者尤其合理。然而，所提出的病例表明，[99mTc]Tc-MIBI 的局部摄取增加并不总是与癌细胞的存在相关，并且可能是由治疗后变化引起的。
The oncophilic nature of [99mTc]Tc-MIBI makes this radiopharmaceutical useful in cancer diagnostics, with particular emphasis on breast cancer. Increased uptake of [99mTc]Tc-MIBI in tests performed for non-oncological indications always raises the suspicion of its neoplasmatic character and requires further clinical diagnostics, which is especially justified in patients with a previous history of cancer. However, the presented case illustrates that focally increased uptake of [99mTc]Tc-MIBI is not always associated with the presence of cancer cells and may result from post-therapeutic changes.